Citadel Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-288,700
| Closed | -$658K | – | 15551 |
|
|
2024
Q2 | $658K | Buy |
288,700
+258,000
| +840% | +$986K | ﹤0.01% | 7468 |
|
|
2024
Q1 | $133K | Sell |
30,700
-8,900
| -22% | -$31K | ﹤0.01% | 10956 |
|
|
2023
Q4 | $121K | Buy |
39,600
+30,700
| +345% | +$57.7K | ﹤0.01% | 10693 |
|
|
2023
Q3 | $12.8K | Sell |
8,900
-12,300
| -58% | -$23.8K | ﹤0.01% | 12947 |
|
|
2023
Q2 | $52.8K | Buy |
21,200
+5,400
| +34% | +$14.8K | ﹤0.01% | 11734 |
|
|
2023
Q1 | $42.3K | Sell |
15,800
-8,100
| -34% | -$38.9K | ﹤0.01% | 12375 |
|
|
2022
Q4 | $130K | Buy |
23,900
+7,400
| +45% | +$62K | ﹤0.01% | 10832 |
|
|
2022
Q3 | $206K | Buy |
16,500
+5,700
| +53% | +$65.1K | ﹤0.01% | 10352 |
|
|
2022
Q2 | $53K | Sell |
10,800
-1,900
| -15% | -$10.5K | ﹤0.01% | 11903 |
|
|
2022
Q1 | $97K | Sell |
12,700
-12,500
| -50% | -$119K | ﹤0.01% | 12316 |
|
|
2021
Q4 | $257K | Sell |
25,200
-12,000
| -32% | -$153K | ﹤0.01% | 11282 |
|
|
2021
Q3 | $499K | Sell |
37,200
-6,000
| -14% | -$97.8K | ﹤0.01% | 9871 |
|
|
2021
Q2 | $948K | Sell |
43,200
-2,200
| -5% | -$48.9K | ﹤0.01% | 8501 |
|
|
2021
Q1 | $1.09M | Sell |
45,400
-60,300
| -57% | -$1.4M | ﹤0.01% | 7900 |
|
|
2020
Q4 | $1.9M | Buy |
105,700
+8,800
| +9% | +$131K | ﹤0.01% | 5444 |
|
|
2020
Q3 | $1.12M | Buy |
+96,900
| New | +$1.6M | ﹤0.01% | 5841 |
|
Citadel Advisors's GTHX Position: Q3 2024 in Review
Citadel Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 239 shares — an estimated $545 sold.
Citadel Advisors first reported a position in GTHX in Q1 2018 and held it in 25 quarters. The position peaked at $4.62M in Q1 2019. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Citadel Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Citadel Advisors sold 239 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $545.
- Citadel Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 25 quarters.
- Citadel Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $4.62M in Q1 2019.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.